PPARG and arrhythmogenic right ventricular cardiomyopathy: Interestingly, since right ventricular dysplasia has been linked to changes in PPAR-γ-dependent pathways in cardiomyocytes energetic metabolism leading to myosin dysfunction [80], pioglitazone has been proposed as a possible therapy for this condition, by acting through alterations in PPAR-γ-dependent Wnt/β-catenin canonical pathway [81].